Please assess the completion status of the following clinical trial:

Trial Title: A Study of the Safety and Tolerance of Three Doses of G17DT in Metastatic Colorectal Cancer

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: None
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Patients aged 18 years or over with histologically verified adenocarcinoma of colon or rectum.~* Recurrent of metastatic disease not amenable to curative surgery and/or radiotherapy.~* Life expectancy greater than 3 months.~* Karnofsky Index Score greater than or equal to 50%.~* Written informed consent obtained.~Exclusion Criteria:~* Neoplastic lesions other than colorectal cancer (except treated basal cell carcinoma of the skin or cancer of the uterine cervix, through Stage I.~* Acute intercurrent illness.~* Patient considered to be a medical risk because of non-malignant systemic disease or grossly abnormal laboratory results.~* Patients who had received any other anticancer therapy within 3 months.~* Factor liable to alter the serum gastrin concentration or affect intra-gastric acidity, for instance concomitant therapy with H2 receptor antagonist drugs, proton pump inhibitors, or previous gastric surgery.~* Patients immunologically compromised including those on corticosteroid therapy.~* Women of child-bearing age.~* Positive immediate hypersensitivity reaction to skin testing with study medication.~* Patients unable to complete the diary book~* Haematogical Status Haemoglobin count less than 10g/dL White Blood Cell count less than 4.0 x 10\^9/L Platelet count less than 100 x 10\^9/L

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 100µg dose of G17DT (Type: EXPERIMENTAL): Patients in this arm received a 100µg dose of G17DT via intramuscular injection.
- 200µg dose of G17DT (Type: EXPERIMENTAL): Patients in this arm received a 200 µg dose of G17DT via intramuscular injection.
- 500µg dose of G17DT (Type: EXPERIMENTAL): Patients in this arm received a 500µg dose of G17DT via intramuscular injection.

Based on this trial design, predict the completion outcome and termination type (if applicable).